Valuation : Bolt Biotherapeutics, Inc.

Market Cap 7.4M 6.38M 6.01M 5.48M 10.24M 699M 10.31M 71.17M 27.62M 357M 27.78M 27.17M 1.17B P/E 2026 *
-0.16x
P/E 2027 * -0.19x
Enterprise Value 7.4M 6.38M 6.01M 5.48M 10.24M 699M 10.31M 71.17M 27.62M 357M 27.78M 27.17M 1.17B EV / Sales 2026 *
37x
EV / Sales 2027 * 2.11x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day+2.34%
1 week-1.75%
Current month-1.26%
1 month-1.26%
3 months-15.12%
6 months-9.03%
Current year-28.13%
1 week 3.74
Extreme 3.74
4.27
1 month 3.13
Extreme 3.13
4.27
Current year 3.13
Extreme 3.13
7.2
1 year 3.13
Extreme 3.13
7.2
3 years 3.13
Extreme 3.13
31.2
5 years 3.13
Extreme 3.13
385.7
10 years 3.13
Extreme 3.13
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 15/05/2024
Chief Executive Officer 55 15/05/2024
Chief Operating Officer 61 15/05/2024
Director TitleAgeSince
Director/Board Member 64 01/12/2020
Director/Board Member 55 15/05/2024
Chairman 56 04/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
10/06/26 Free

Chairman

5,000 0.2602%
28/01/26 Free

Chief Operating Officer

10,000 0.5210%
28/01/26 Buy

Chief Executive Officer

20,125 1.0485%
Change 5-day change 1-year change 3-year change Capi.($)
+2.34%-1.75%-18.76%-82.30% 7.4M
+1.03%-2.05%+39.28%+94.60% 68.87B
+1.31%+0.55%+49.48%+92.12% 65.29B
-0.20%+4.16%-11.89%+379.47% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-1.32%-7.68%+2.42%-15.70% 26.08B
+1.01%+1.38%+26.48%-17.50% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+1.50%+7.58%+60.85%+166.95% 14.5B
Average +1.29%-2.60%+41.46%+157.14% 28.04B
Weighted average by Cap. +1.09%-2.12%+42.78%+142.50%

Financials

2026 *2027 *
Net sales 200K 173K 163K 148K 277K 18.89M 279K 1.92M 747K 9.66M 751K 735K 31.73M 3.5M 3.02M 2.84M 2.59M 4.84M 331M 4.88M 33.67M 13.07M 169M 13.14M 12.86M 555M
Net income -47.4M -40.89M -38.52M -35.1M -65.6M -4.48B -66.09M -456M -177M -2.29B -178M -174M -7.52B -47.5M -40.98M -38.6M -35.17M -65.74M -4.49B -66.23M -457M -177M -2.29B -178M -174M -7.54B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
03/09/26 $3.930 +2.34% 2,894
02/09/26 $3.840 -5.65% 34,539
01/09/26 $4.070 +2.26% 8,087
31/08/26 $3.980 +4.33% 4,958
28/08/26 $3.815 -4.62% 24,986
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.840USD
Average target price
29.00USD
Spread / Average Target
+655.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock